Phase I, Arteriocyte Magellan MAR01 Therapy - Compartment Syndrome and Battlefield Trauma (Magellan MAR01)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01837264|
Recruitment Status : Completed
First Posted : April 23, 2013
Last Update Posted : April 13, 2017
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Compartment syndrome (CS) is a condition resulting from increased pressure within a compartment, which compromises circulation and can lead to critical limb ischemia. CS is one of the biggest medical challenges that our soldiers face after battlefield related injuries. Chronic or exercise-induced compartment syndrome (CS)rarely requires treatment; acute compartment syndrome is a medical emergency requiring surgery. Treatment of compartment syndrome is limited to fasciotomy, which relieves the pressure.The study purpose is to evaluate the feasibility and safety of the administration of marrow-derived autologous bone marrow concentrate and PRP gel generated by a point of care marrow separation system for the treatment of compartment syndrome. And to show this treatment possibly enhances wound healing, bone healing, perfusion, infection control, and the return of limb function in patients with CS.
Stem Cell and regenerative medicine development efforts for therapeutic angiogenesis and wound healing have predominantly focused on the mechanism of action of a single stem cell population to achieve neovascularization and improve tissue perfusion. It is well documented that other cells, including platelets, are efficient carriers of growth factors (VEGF-PDGF, bFGF, and SDF-1) and play active roles in angiogenesis and wound healing. Arteriocyte's development efforts focus on concentration of autologous bone marrow-derived stem cells and platelets for delivery to the site of injury in a concentration sufficient to effect local tissue revascularization and repair. These products provide for the rapid, bedside preparation of autologous PRP and bone marrow stem cell concentrate.
This clinical trial with the Magellan® System is for the preparation of autologous cell concentrate for the treatment of wound, tissue and bone healing, improved perfusion, infection control, and the return of limb function in patients at risk of amputation.
|Condition or disease||Intervention/treatment||Phase|
|Compartment Syndrome||Device: Magellan®||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||5 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase I, Arteriocyte Magellan MAR01 Therapy - Compartment Syndrome and Battlefield Trauma Study Protocol|
|Study Start Date :||January 2013|
|Actual Primary Completion Date :||September 2016|
|Actual Study Completion Date :||January 31, 2017|
|Experimental: Bone Marrow Cell Concentrate||
- Time to treatment failure or death [ Time Frame: 12 months ]
- Measurement of rate of infection in the study population
- Complications due to wound and/or therapy
- Amputation of limb and/or death
- Perfusion and quality of life measurements [ Time Frame: 12 months ]
Wound healing (rate and qualitative healing assessment)
- Bone healing (Radiographic assessment)
- Tissue perfusion (ABI; TcPO2)
- Limb pain (pain score assessment)
- Functional performance vs. uninjured limb
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 65 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Is able to provide signed, written informed consent prior to study entry
- Speaks English
- compartment fasciotomy of tibial compartment
- Sufficient skin for primary closure
- Is male or female, 18 - 65 years of age
- ABI less than 0.7, ankle pressure < 50 mmHg, or toe pressure < 30 mmHg.
- TcPO2 < 40 mmHg.
- Female subjects must be of non childbearing potential (defined as postmenopausal for at least 1 year or surgically sterile [bilateral tubal ligation, bilateral oophorectomy or hysterectomy]) or must be using adequate contraception (practicing one of the following methods of birth control):
Total abstinence from sexual intercourse (minimum of one complete menstrual cycle before study entry), A partner who is physically unable to impregnate the subject (e.g., vasectomized)Contraceptives (oral, parenteral, or transdermal) for 3 consecutive months prior to patient's cell concentrate administration, Intrauterine device (IUD), or Double barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream)
- If female of childbearing potential, subject must have a negative urine pregnancy test at screening
- Confirmation of age-appropriate cancer screening consistent with the American Cancer Society guidelines.
- Prior compartment syndrome fracture of same limb
- Previous fracture of the same limb
- Any contraindication to stem cell or platelet-rich plasma therapy.
- Have an active malignancy or have undergone treatment for a malignancy in the preceding 5 years, with the exception of successful treatment of non-melanoma skin cancer.
- Stage 4 or greater chronic kidney disease (eGFR < 30 ml/min, MDRD estimate).
- Unwilling or unable to comply with follow-up visits.
- Is unable to refrain from nicotine, caffeine and alcohol for a period beginning 24 hours prior to the treatment visit
- Has received an investigational medication or other study trial participation within 30 days prior to the Treatment Visit
- Non-English Speaker
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01837264
|United States, Illinois|
|Advocate Christ Medical Center|
|Oak Lawn, Illinois, United States, 60453|
|Study Director:||Brian Barnes, PhD||Arteriocyte, Inc.|
|Responsible Party:||Arteriocyte, Inc.|
|Other Study ID Numbers:||
|First Posted:||April 23, 2013 Key Record Dates|
|Last Update Posted:||April 13, 2017|
|Last Verified:||January 2017|
Autologous Platelet Rich Plasma